Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perrigo Fuels “Growth Engine” With Spending On New Product Pipeline

This article was originally published in The Tan Sheet

Executive Summary

Perrigo plans to file more than 10 abbreviated new drug applications before July this year, President and CEO Joe Papa said Feb. 5

You may also be interested in...



Sanofi Lawsuit Delays OTC Nasacort Generic Competition

Sanofi says with Nasacort Allergy 24HR available at retailers nationwide and online, the firm withdrew its litigation against FDA, which appears to have slowed development of private-label equivalents.

Sanofi Lawsuit Delays OTC Nasacort Generic Competition

Sanofi says with Nasacort Allergy 24HR available at retailers nationwide and online, the firm withdrew its litigation against FDA, which appears to have slowed development of private-label equivalents.

Sanofi Lawsuit Delays OTC Nasacort Generic Competition

Sanofi says with Nasacort Allergy 24HR available at retailers nationwide and online, the firm withdrew its litigation against FDA, which appears to have slowed development of private-label equivalents.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS101351

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel